Screener
Alnylam Pharmaceuticals ALNY Preferred Stock, Shares Authorized
Preferred Stock, Shares Authorized at other companies
Other financials
Where this comes from
Reported directly by Alnylam Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:PreferredStockSharesAuthorized.
The source filing: Alnylam Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 8:11 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001178670-26-000062
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Total liabilities | 4,204,651 | 4,177,155 |
| Commitments and contingencies (Note 12) | ||
| Stockholders' equity: | ||
| Preferred stock, $0.01 par value per share, 5,000 shares authorized and no shares issued and outstanding as of June 30, 2026 and December 31, 2025 | — | — |
| Common stock, $0.01 par value per share, 250,000 shares authorized; 133,734 shares issued and outstanding as of June 30, 2026; 132,376 shares issued and outstanding as of December 31, 2025 | 1,337 | 1,324 |
| Additional paid-in capital | 7,716,958 | 7,510,473 |
| Accumulated other comprehensive loss | (32,138) | (20,097) |
| Accumulated deficit | (6,332,039) | (6,702,524) |
Cover / Front Matter
FAQ
- What is Alnylam Pharmaceuticals's preferred stock, shares authorized?
- Alnylam Pharmaceuticals (ALNY) reported preferred stock, shares authorized of $5M in Q2 2026.
- How has Alnylam Pharmaceuticals's preferred stock, shares authorized changed year-over-year?
- Alnylam Pharmaceuticals's preferred stock, shares authorized decreased by 0.0% year-over-year, from $5M to $5M.
- What is the long-term trend for Alnylam Pharmaceuticals's preferred stock, shares authorized?
- Over 5 years (2020 to 2025), Alnylam Pharmaceuticals's preferred stock, shares authorized has grown at a 0.0% compound annual growth rate (CAGR), from $5M to $5M.
Ask your AI about Alnylam Pharmaceuticals's preferred stock, shares authorized.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude